Evidence map›Paper›PMID 42174129›Full record

ArticleActa pharmacologica Sinica2026

FLRT2 promotes foam cell formation and atherosclerosis by inhibiting USP22-mediated ABCA1 deubiquitination.

Jing-Quan Zhou, Hui-Xuan Zhang, Li-Zhen Guo, Jie Wang, Yan-Yu Chen, En-Dong Jiang, Juan Peng, Hong Gao, Yuan-Hong Sun, Ming-Yan Zhu and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jing-Quan Zhou *Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Hui-Xuan Zhang *Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Li-Zhen Guo *Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Jie WangDepartment of Cardiovascular Medicine, the Second Affiliated Hospital, University of South China, Hengyang, 421001, China.
Yan-Yu ChenDepartment of Cardiovascular Medicine, the Second Affiliated Hospital, University of South China, Hengyang, 421001, China.
En-Dong JiangDepartment of Cardiovascular Medicine, the Second Affiliated Hospital, University of South China, Hengyang, 421001, China.
Juan PengKey Laboratory for Arteriosclerology of Hunan Province, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, School of Basic Medical Sciences, Hengyang Medical School, Institute of Cardiovascular Disease, University of South China, Hengyang, 421001, China.
Hong GaoDepartment of Cardiovascular Medicine, the Second Affiliated Hospital, University of South China, Hengyang, 421001, China.
Yuan-Hong SunKey Laboratory for Arteriosclerology of Hunan Province, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, School of Basic Medical Sciences, Hengyang Medical School, Institute of Cardiovascular Disease, University of South China, Hengyang, 421001, China.
Ming-Yan ZhuDepartment of Cardiovascular Medicine, the Second Affiliated Hospital, University of South China, Hengyang, 421001, China.
Jian-Ye PengDepartment of Cardiovascular Medicine, the Second Affiliated Hospital, University of South China, Hengyang, 421001, China.
Gao-Feng ZengDepartment of Cardiovascular Medicine, the Second Affiliated Hospital, University of South China, Hengyang, 421001, China.
Yuan-Ye DangGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China. dangyuanye@163.com.
Kong-Yang MaShenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases, Centre for Infection and Immunity Studies (CIIS), School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen, 518107, China. makyang@mail.sysu.edu.cn.
Xiao-Yan DaiGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China. xdai@usc.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atherosclerosis is a chronic inflammatory disease characterized by the accumulation of foam cells within the arterial wall. Despite substantial progress, the molecular mechanisms governing foam cell formation remain incompletely understood. Here, we identify fibronectin leucine-rich transmembrane protein 2 (FLRT2) as a previously unrecognized regulator of macrophage-driven atherogenesis through the facilitation of foam cell formation. FLRT2 expression was markedly elevated in macrophages within both murine and human atherosclerotic plaques. Functionally, adenovirus-mediated FLRT2 overexpression aggravated atherosclerotic lesion development in Apoe

Indexed as

AtherosclerosisATP Binding Cassette Transporter 1Foam CellsMembrane ProteinsUbiquitin ThiolesteraseAnimalsHumansMacrophagesMaleMiceMice, Inbred C57BLUbiquitinationABCA1 protein, humanAbca1 protein, mouseATP Binding Cassette Transporter 1Membrane ProteinsUbiquitin ThiolesteraseABCA1atherosclerosisFLRT2foam cellmacrophageUSP22

Identifiers

PMID42174129
PMCPMC13388717

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.